Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, London W2 1NY, UK.
Faculty of Medicine, University of Birmingham, Birmingham B15 2TT, UK.
Int J Mol Sci. 2022 Jul 27;23(15):8307. doi: 10.3390/ijms23158307.
Non-alcoholic fatty liver disease (NAFLD) represents an increasing cause of liver disease, affecting one-third of the population worldwide. Despite many medications being in the pipeline to treat the condition, there is still no pharmaceutical agent licensed to treat the disease. As intestinal bacteria play a crucial role in the pathogenesis and progression of liver damage in patients with NAFLD, it has been suggested that manipulating the microbiome may represent a therapeutical option. In this review, we summarise the latest evidence supporting the manipulation of the intestinal microbiome as a potential therapy for treating liver disease in patients with NAFLD.
非酒精性脂肪性肝病（NAFLD）是一种日益常见的肝脏疾病，影响着全球三分之一的人口。尽管有许多药物正在研发中用于治疗这种疾病，但目前还没有获得批准用于治疗该疾病的药物。由于肠道细菌在 NAFLD 患者的肝损伤发病机制和进展中起着至关重要的作用，因此有人提出，操纵微生物组可能是一种治疗选择。在这篇综述中，我们总结了支持肠道微生物组操纵作为治疗 NAFLD 患者肝脏疾病的潜在疗法的最新证据。
